---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-037209"
form_type: "8-K"
ticker: "QCLS"
cik: "0001321834"
company_name: "Q/C TECHNOLOGIES, INC."
filed_at: "2023-10-13T23:59:59+00:00"
generated_at: "2026-06-09T23:54:44.693421+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# MyMD Pharmaceuticals receives Nasdaq deficiency notice for bid price below $1.00

## Summary
- Received Nasdaq letter on Oct 11, 2023, for failing to maintain $1.00 closing bid price for 30 consecutive business days.
- Has until April 8, 2024 (180-day compliance period) to regain compliance by achieving $1.00 closing bid for 10 consecutive days.
- If not compliant by April 8, may receive additional 180-day cure period if meeting other listing standards.
- No immediate delisting; stock continues trading on Nasdaq Capital Market.

## SEC filing metadata
- accession: 0001493152-23-037209
- form_type: 8-K
- ticker: QCLS
- cik: 0001321834
- company_name: Q/C TECHNOLOGIES, INC.
- filed_at: 2023-10-13T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1321834/000149315223037209/0001493152-23-037209-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1321834/000149315223037209/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-037209
- JSON: https://secwatch.observer/filing/0001493152-23-037209.json
- Plain text: https://secwatch.observer/filing/0001493152-23-037209.txt

## Key facts
- Listing & Compliance Notices
  Q/C TECHNOLOGIES, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2), 5810(c)(3)(A)
  source text: October 11, 2023, MyMD Pharmaceuticals, Inc. (the “Company”) received a letter from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock for the 30 consecutive business days between August 29, 2023, to October 10, 2023, the Company did not meet the minimum bid price of $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2). The letter also indicated that the Company will be provided with a compliance period of 180 calendar days
  evidence_url: https://www.sec.gov/Archives/edgar/data/1321834/000149315223037209/0001493152-23-037209-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.